“…Several of these epidemiological studies [41], [42], [43], [45], [46], [47], [48] demonstrated that EHEC O157 carrying stx2a (with or without stx2c ) rather than stx2c were more frequent among clinical isolates, in agreement with the results presented here. Recently, Kawano et al [48] along with others [43], [45], [46] suggested that EHEC O157 carrying stx2c were associated with asymptomatic individuals and mild disease however it is also isolated from patients with severe disease (bloody diarrhea, HC and HUS) as shown by others [23], [40], [41], [44], [47], [49]. Furthermore, Fuller et al recently demonstrated that purified Stx2a is more potent than Stx2c against primary human kidney cell lines and in mouse models [42].…”